You are here

  • Home
  • Archive
  • Volume 76, Issue 11
  • Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

Article metrics

Article menu

Download PDFPDF

Clinical and epidemiological research
Extended report
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

 

Online download statistics by month:

Online download statistics by month: August 2017 to August 2024

AbstractFullPdf
Aug 201713411344436
Sep 2017740790376
Oct 2017857883364
Nov 2017477479260
Dec 2017417417112
Jan 2018276277112
Feb 201834633876
Mar 2018334330117
Apr 201830230284
May 201826927187
Jun 201827527591
Jul 201821421478
Aug 201822322389
Sep 201818318379
Oct 201821121192
Nov 2018227227102
Dec 201821821889
Jan 201912812068
Feb 201915815369
Mar 2019167165104
Apr 201915715685
May 201914914977
Jun 201911711887
Jul 201916015575
Aug 201915714594
Sep 201912211069
Oct 2019162146105
Nov 201914614285
Dec 201916215385
Jan 202011811267
Feb 202011411458
Mar 202011611662
Apr 2020135136126
May 2020115115101
Jun 2020939391
Jul 202010210179
Aug 2020838193
Sep 20209290100
Oct 202013013091
Nov 202012812684
Dec 202010510570
Jan 202111111173
Feb 2021969667
Mar 2021808092
Apr 2021888862
May 202110410274
Jun 2021797974
Jul 2021666653
Aug 2021767667
Sep 2021848372
Oct 20219999100
Nov 2021909074
Dec 2021767675
Jan 2022576748
Feb 20229410180
Mar 202213013994
Apr 2022697756
May 202211111896
Jun 2022939355
Jul 202210610963
Aug 2022859164
Sep 2022969959
Oct 2022717247
Nov 2022626263
Dec 2022595944
Jan 2023717139
Feb 2023676640
Mar 2023545868
Apr 2023454658
May 2023373735
Jun 2023444431
Jul 2023444533
Aug 2023536149
Sep 2023565626
Oct 2023878736
Nov 202317918045
Dec 202344844734
Jan 202417917143
Feb 202413712929
Mar 2024959565
Apr 2024626639
May 2024696735
Jun 2024595942
Jul 2024767623
Aug 20245858116
Total14028140657207